Skip directly to content

Worldwide Antiretroviral Drug Sales 2006

Addthis

TAGline September 2007

Drug

Company

$ Million

Change From 2005

Notes

Truvada

Gilead

1,194

+210%

 

Kaletra

Abbott

1,135

+13%

 

Combivir

GlaxoSmithKline

977

-8%

 

Reyataz

Bristol-Myers Squibb

931

+34%

 

Sustiva

Bristol-Myers Squibb

791

+16%

Includes $76 million related to Atripla sales

Viread

Gilead

689

-12%

 

Trizivir

GlaxoSmithKline

496

-10%

 

Epzicom

GlaxoSmithKline

446

+207%

 

Epivir

GlaxoSmithKline

374

-11%

 

Viramune

Boehringer-Ingelheim

353

-4%

Estimate, based on 276 Euros

Crixivan

Merck

327

-6%

 

Fuzeon

Roche

250

+19%

Estimate, based on 312 Swiss Francs

Lexiva/Agenerase

GlaxoSmithKline

242

+19%

 

Ziagen

GlaxoSmithKline

216

-13%

 

Atripla

Gilead

206

-

Gilead recorded 100% of Atripla sales, then paid BMS $76 million for the efavirenz

Zerit

Bristol-Myers Squibb

155

-18%

 

Invirase/Fortovase

Roche

145

+28%

Estimate, based on 182 Swiss Francs

Aptivus

Boehringer-Ingelheim

67

-

Estimate, based on 53 Euros

Emtriva

Gilead

36

-13%

 

TOTAL

 

9,030

+14%

 

*Does not include unreported drugs (Videx, Norvir, Viracept, Rescriptor, Retrovir)

Source: AIDSMeds.com based on SEC filings